HRP20110047T1 - Novi derivati 5-supstituiranog 7-amino-[1,3]tiazolo[4,5-d]pirimidina - Google Patents
Novi derivati 5-supstituiranog 7-amino-[1,3]tiazolo[4,5-d]pirimidina Download PDFInfo
- Publication number
- HRP20110047T1 HRP20110047T1 HR20110047T HRP20110047T HRP20110047T1 HR P20110047 T1 HRP20110047 T1 HR P20110047T1 HR 20110047 T HR20110047 T HR 20110047T HR P20110047 T HRP20110047 T HR P20110047T HR P20110047 T1 HRP20110047 T1 HR P20110047T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino
- compound
- formula
- thiazolo
- thio
- Prior art date
Links
- -1 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine Chemical class 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 32
- 150000003839 salts Chemical class 0.000 claims abstract 13
- 239000003814 drug Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 238000011321 prophylaxis Methods 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- 238000006243 chemical reaction Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 2
- PDKBAEAFZLXVQK-AWKYBWMHSA-N (2r)-2-[[2-amino-5-(1-phenylethylsulfanyl)-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]-methylamino]-4-methylpentan-1-ol Chemical compound N=1C=2N=C(N)SC=2C(N(C)[C@@H](CO)CC(C)C)=NC=1SC(C)C1=CC=CC=C1 PDKBAEAFZLXVQK-AWKYBWMHSA-N 0.000 claims 1
- ZMQSLMZOWVGBSM-TYZXPVIJSA-N (2r)-2-[[2-amino-5-(1-phenylethylsulfanyl)-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound N=1C=2N=C(N)SC=2C(N[C@@H](CO)CC(C)C)=NC=1SC(C)C1=CC=CC=C1 ZMQSLMZOWVGBSM-TYZXPVIJSA-N 0.000 claims 1
- SZCVFEVNVFBNBL-GICMACPYSA-N (2r)-2-[[2-amino-5-(1-phenylpropylsulfanyl)-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound N=1C(N[C@@H](CO)CC(C)C)=C2SC(N)=NC2=NC=1SC(CC)C1=CC=CC=C1 SZCVFEVNVFBNBL-GICMACPYSA-N 0.000 claims 1
- LBAMGFHXEZOCSA-WDEREUQCSA-N (2r)-2-[[2-amino-5-[(1s)-1-(2-fluorophenyl)ethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-fluoro-4-methylpentan-1-ol Chemical compound C1([C@@H](SC=2N=C3N=C(N)SC3=C(N[C@@H](CO)CC(C)(C)F)N=2)C)=CC=CC=C1F LBAMGFHXEZOCSA-WDEREUQCSA-N 0.000 claims 1
- PQYZCJMYDYNLKP-NWDGAFQWSA-N (2r)-2-[[2-amino-5-[(1s)-1-(2-fluorophenyl)ethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound C1([C@H](C)SC=2N=C(C=3SC(N)=NC=3N=2)N[C@@H](CO)CC(C)C)=CC=CC=C1F PQYZCJMYDYNLKP-NWDGAFQWSA-N 0.000 claims 1
- HNGCDCABVYTVAE-WDEREUQCSA-N (2r)-2-[[2-amino-5-[(1s)-1-(2-fluorophenyl)ethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]pentan-1-ol Chemical compound C1([C@H](C)SC=2N=C(C=3SC(N)=NC=3N=2)N[C@@H](CO)CCC)=CC=CC=C1F HNGCDCABVYTVAE-WDEREUQCSA-N 0.000 claims 1
- GDKZGPOPQDQWKT-SMDDNHRTSA-N (2r)-2-[[2-amino-5-[(1s)-1-(3-fluorophenyl)ethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound C1([C@H](C)SC=2N=C(C=3SC(N)=NC=3N=2)N[C@@H](CO)CC(C)C)=CC=CC(F)=C1 GDKZGPOPQDQWKT-SMDDNHRTSA-N 0.000 claims 1
- ZJTOCCMPRIUOGK-GXTWGEPZSA-N (2r)-2-[[2-amino-5-[(1s)-1-(3-methylsulfonylphenyl)ethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound C1([C@H](C)SC=2N=C(C=3SC(N)=NC=3N=2)N[C@@H](CO)CC(C)C)=CC=CC(S(C)(=O)=O)=C1 ZJTOCCMPRIUOGK-GXTWGEPZSA-N 0.000 claims 1
- SQLWCNPRGCHCDW-WCQYABFASA-N (2r)-2-[[2-amino-5-[(1s)-1-phenylethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-fluoro-4-methylpentan-1-ol Chemical compound C1([C@@H](SC=2N=C3N=C(N)SC3=C(N[C@@H](CO)CC(C)(C)F)N=2)C)=CC=CC=C1 SQLWCNPRGCHCDW-WCQYABFASA-N 0.000 claims 1
- ZMQSLMZOWVGBSM-GXTWGEPZSA-N (2r)-2-[[2-amino-5-[(1s)-1-phenylethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound C1([C@H](C)SC=2N=C(C=3SC(N)=NC=3N=2)N[C@@H](CO)CC(C)C)=CC=CC=C1 ZMQSLMZOWVGBSM-GXTWGEPZSA-N 0.000 claims 1
- OBTCRZSOJNBQII-WCQYABFASA-N (2r)-2-[[2-amino-5-[(1s)-1-phenylethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]pentan-1-ol Chemical compound C1([C@H](C)SC=2N=C(C=3SC(N)=NC=3N=2)N[C@@H](CO)CCC)=CC=CC=C1 OBTCRZSOJNBQII-WCQYABFASA-N 0.000 claims 1
- BVIAWIVOFOEULB-PIJUOVFKSA-N (2r)-2-[[2-amino-5-[1-(2-chlorophenyl)ethylsulfanyl]-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound N=1C=2N=C(N)SC=2C(N[C@@H](CO)CC(C)C)=NC=1SC(C)C1=CC=CC=C1Cl BVIAWIVOFOEULB-PIJUOVFKSA-N 0.000 claims 1
- ZMMDDWBVYKJHNY-TYZXPVIJSA-N (2r)-2-[[2-amino-5-[1-(3-methoxyphenyl)ethylsulfanyl]-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound COC1=CC=CC(C(C)SC=2N=C3N=C(N)SC3=C(N[C@@H](CO)CC(C)C)N=2)=C1 ZMMDDWBVYKJHNY-TYZXPVIJSA-N 0.000 claims 1
- BGLLFCTTXBNCFY-SBXXRYSUSA-N (2r)-2-[[2-amino-5-[1-[3-(trifluoromethyl)phenyl]ethylsulfanyl]-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound N=1C=2N=C(N)SC=2C(N[C@@H](CO)CC(C)C)=NC=1SC(C)C1=CC=CC(C(F)(F)F)=C1 BGLLFCTTXBNCFY-SBXXRYSUSA-N 0.000 claims 1
- PNKYTKPWPKRAKI-SMDDNHRTSA-N 3-[(1s)-1-[[2-amino-7-[[(2r)-1-hydroxypentan-2-yl]amino]-[1,3]thiazolo[4,5-d]pyrimidin-5-yl]sulfanyl]ethyl]benzonitrile Chemical compound C1([C@H](C)SC=2N=C(C=3SC(N)=NC=3N=2)N[C@@H](CO)CCC)=CC=CC(C#N)=C1 PNKYTKPWPKRAKI-SMDDNHRTSA-N 0.000 claims 1
- XQHOYGCLIKGICN-SBXXRYSUSA-N 3-[1-[[2-amino-7-[[(2r)-1-hydroxy-4-methylpentan-2-yl]amino]-[1,3]thiazolo[4,5-d]pyrimidin-5-yl]sulfanyl]ethyl]benzamide Chemical compound N=1C=2N=C(N)SC=2C(N[C@@H](CO)CC(C)C)=NC=1SC(C)C1=CC=CC(C(N)=O)=C1 XQHOYGCLIKGICN-SBXXRYSUSA-N 0.000 claims 1
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 claims 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000007214 atherothrombosis Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 208000030613 peripheral artery disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0500767 | 2005-04-06 | ||
| PCT/SE2006/000399 WO2006107258A1 (en) | 2005-04-06 | 2006-04-03 | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110047T1 true HRP20110047T1 (hr) | 2011-03-31 |
Family
ID=37073739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110047T HRP20110047T1 (hr) | 2005-04-06 | 2011-01-21 | Novi derivati 5-supstituiranog 7-amino-[1,3]tiazolo[4,5-d]pirimidina |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US7947693B2 (ru) |
| EP (1) | EP1869056B1 (ru) |
| JP (1) | JP5165553B2 (ru) |
| KR (1) | KR101335055B1 (ru) |
| CN (1) | CN101193897B (ru) |
| AR (1) | AR055890A1 (ru) |
| AT (1) | ATE487727T1 (ru) |
| AU (1) | AU2006231836B2 (ru) |
| BR (1) | BRPI0609738A2 (ru) |
| CA (1) | CA2604017C (ru) |
| CY (1) | CY1111316T1 (ru) |
| DE (1) | DE602006018124D1 (ru) |
| DK (1) | DK1869056T3 (ru) |
| ES (1) | ES2354450T3 (ru) |
| HK (1) | HK1118556A1 (ru) |
| HR (1) | HRP20110047T1 (ru) |
| IL (1) | IL185912A0 (ru) |
| MX (1) | MX2007012060A (ru) |
| NO (1) | NO20075603L (ru) |
| NZ (1) | NZ561460A (ru) |
| PL (1) | PL1869056T3 (ru) |
| PT (1) | PT1869056E (ru) |
| RS (1) | RS51581B (ru) |
| RU (1) | RU2419623C2 (ru) |
| SA (1) | SA06270072B1 (ru) |
| SI (1) | SI1869056T1 (ru) |
| TW (1) | TW200714605A (ru) |
| UA (1) | UA90707C2 (ru) |
| UY (1) | UY29454A1 (ru) |
| WO (1) | WO2006107258A1 (ru) |
| ZA (1) | ZA200708187B (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1806145B1 (en) | 2004-10-29 | 2017-08-16 | Eisai R&D Management Co., Ltd. | Remedy for inflammatory diseases |
| AR053347A1 (es) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| TW200820973A (en) | 2006-09-29 | 2008-05-16 | Astrazeneca Ab | Novel compounds 480 |
| KR20090057075A (ko) | 2006-09-29 | 2009-06-03 | 아스트라제네카 아베 | 신규한 5,7-이치환된 [1,3]티아졸로[4,5-ｄ]피리미딘-2(3ｈ)-아민 유도체 및 요법에서 그의 용도 |
| CN101959866B (zh) | 2008-03-07 | 2013-10-02 | 方济各安吉利克化学联合股份有限公司 | 1-苄基-3-羟基甲基吲唑衍生物及其在治疗基于mcp-1和cx3cr1表达的疾病中的用途 |
| DK2262778T5 (da) | 2008-03-07 | 2020-06-08 | Acraf | 1-benzyl-3-hydroxymethylindazolderivativer og brug deraf i behandling af sygdomme baseret på ekspression af mcp-1, cx3cr1 og p40 |
| BRPI0907977A2 (pt) | 2008-03-07 | 2015-08-04 | Acraf | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças |
| TW201100411A (en) | 2009-05-21 | 2011-01-01 | Chlorion Pharma Inc | Pyrimidines as novel therapeutic agents |
| JO3437B1 (ar) | 2009-10-30 | 2019-10-20 | Esai R & D Man Co Ltd | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها |
| US8435993B2 (en) | 2010-12-07 | 2013-05-07 | Philadelphia Health And Education Corporation | Methods of inhibiting metastasis from cancer |
| US8476301B2 (en) | 2011-09-13 | 2013-07-02 | Eisai R&D Management Co., Ltd. | Pyrrolidin-3-ylacetic acid derivative |
| TWI543975B (zh) | 2011-09-13 | 2016-08-01 | Eisai R&D Man Co Ltd | Pyrrolidin-3-yl acetic acid derivatives |
| EP2975035B1 (en) | 2013-03-12 | 2017-08-02 | Eisai R&D Management Co., Ltd. | Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof |
| EP3049086A4 (en) * | 2013-09-27 | 2017-02-22 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| US20180222922A1 (en) * | 2015-06-08 | 2018-08-09 | The Johns Hopkins University | Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1) |
| WO2018204370A1 (en) | 2017-05-02 | 2018-11-08 | Drexel University | Cx3cr1 small molecule antagonists, and methods using same |
| GB201807898D0 (en) * | 2018-05-15 | 2018-06-27 | Kancera Ab | New processes and products with increased chiral purity |
| GB201811169D0 (en) * | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
| GB202006849D0 (en) | 2020-05-08 | 2020-06-24 | Kancera Ab | New use |
| WO2024083933A1 (en) | 2022-10-19 | 2024-04-25 | Astrazeneca Ab | 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx 3cr1 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE543978A (ru) * | 1955-01-03 | |||
| US4698327A (en) * | 1985-04-25 | 1987-10-06 | Eli Lilly And Company | Novel glycopeptide derivatives |
| US4643987A (en) * | 1985-08-14 | 1987-02-17 | Eli Lilly And Company | Modified glycopeptides |
| US4639433A (en) * | 1985-08-14 | 1987-01-27 | Eli Lilly And Company | Glycopeptide derivatives |
| CA2031803C (en) | 1989-12-13 | 2001-05-29 | Ramakrishnan Nagarajan | Improvements in or relating to glycopeptide deriveratives |
| US5202328A (en) * | 1991-03-06 | 1993-04-13 | Merck & Co., Inc. | Substituted fused pyrimidinones |
| US5840684A (en) * | 1994-01-28 | 1998-11-24 | Eli Lilly And Company | Glycopeptide antibiotic derivatives |
| AU3213699A (en) * | 1998-04-03 | 1999-10-25 | Du Pont Pharmaceuticals Company | Thiazolo(4,5-d)pyrimidines and pyridines as corticotropin releasing factor (CRF)antagonists |
| DK1073447T3 (da) | 1998-05-01 | 2007-09-03 | Lilly Co Eli | N1-modificerede glycopeptider |
| SE9802729D0 (sv) | 1998-08-13 | 1998-08-13 | Astra Pharma Prod | Novel Compounds |
| SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| JP2003522191A (ja) * | 2000-02-11 | 2003-07-22 | アストラゼネカ・アクチエボラーグ | ケモカイン受容体活性のモジュレーターとしてのピリミジン化合物およびそれらの使用 |
| GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| SE0004110L (sv) * | 2000-11-10 | 2002-05-11 | Forsheda Ab | Tätningsring |
| SE0101082D0 (sv) * | 2001-03-27 | 2001-03-27 | Astrazeneca Ab | Novel use |
| SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| GB0221829D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| JP5591434B2 (ja) * | 2002-12-20 | 2014-09-17 | ゼリス ファーマシューティカルズ インコーポレイテッド | 皮内注射方法 |
| BRPI0415050A (pt) * | 2003-10-07 | 2006-11-28 | Astrazeneca Ab | composto, formulação farmacêutica, método para tratar ou reduzir risco de uma doença ou condição humanas, uso de um composto ou de um sal deste farmaceuticamente aceitável, e, processo para a preparação de um composto ou de um sal deste farmaceuticamente aceitável |
| EP1844054A2 (en) * | 2004-12-17 | 2007-10-17 | AstraZeneca AB | Thiazolopyrimidine compounds for the modulation of chemokine receptor activity |
| AR053347A1 (es) * | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
-
2006
- 2006-03-04 UA UAA200710491A patent/UA90707C2/ru unknown
- 2006-03-27 AR ARP060101169A patent/AR055890A1/es not_active Application Discontinuation
- 2006-03-28 TW TW095110726A patent/TW200714605A/zh unknown
- 2006-03-29 SA SA06270072A patent/SA06270072B1/ar unknown
- 2006-04-03 ES ES06717078T patent/ES2354450T3/es active Active
- 2006-04-03 US US11/910,780 patent/US7947693B2/en active Active
- 2006-04-03 NZ NZ561460A patent/NZ561460A/en not_active IP Right Cessation
- 2006-04-03 WO PCT/SE2006/000399 patent/WO2006107258A1/en active Application Filing
- 2006-04-03 EP EP06717078A patent/EP1869056B1/en active Active
- 2006-04-03 AU AU2006231836A patent/AU2006231836B2/en not_active Ceased
- 2006-04-03 DE DE602006018124T patent/DE602006018124D1/de active Active
- 2006-04-03 DK DK06717078.7T patent/DK1869056T3/da active
- 2006-04-03 JP JP2008505262A patent/JP5165553B2/ja active Active
- 2006-04-03 KR KR1020077022813A patent/KR101335055B1/ko not_active IP Right Cessation
- 2006-04-03 PT PT06717078T patent/PT1869056E/pt unknown
- 2006-04-03 CA CA2604017A patent/CA2604017C/en not_active Expired - Fee Related
- 2006-04-03 AT AT06717078T patent/ATE487727T1/de active
- 2006-04-03 MX MX2007012060A patent/MX2007012060A/es active IP Right Grant
- 2006-04-03 BR BRPI0609738-3A patent/BRPI0609738A2/pt not_active IP Right Cessation
- 2006-04-03 SI SI200630886T patent/SI1869056T1/sl unknown
- 2006-04-03 RU RU2007140551/04A patent/RU2419623C2/ru not_active IP Right Cessation
- 2006-04-03 RS RS20110006A patent/RS51581B/en unknown
- 2006-04-03 PL PL06717078T patent/PL1869056T3/pl unknown
- 2006-04-03 CN CN2006800200726A patent/CN101193897B/zh active Active
- 2006-04-04 UY UY29454A patent/UY29454A1/es not_active Application Discontinuation
-
2007
- 2007-09-11 IL IL185912A patent/IL185912A0/en unknown
- 2007-09-25 ZA ZA200708187A patent/ZA200708187B/xx unknown
- 2007-11-05 NO NO20075603A patent/NO20075603L/no not_active Application Discontinuation
-
2008
- 2008-11-14 HK HK08112536.8A patent/HK1118556A1/xx not_active IP Right Cessation
-
2010
- 2010-12-28 US US12/979,720 patent/US9440992B2/en active Active
-
2011
- 2011-01-13 CY CY20111100040T patent/CY1111316T1/el unknown
- 2011-01-21 HR HR20110047T patent/HRP20110047T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110047T1 (hr) | Novi derivati 5-supstituiranog 7-amino-[1,3]tiazolo[4,5-d]pirimidina | |
| JP2008535835A5 (ru) | ||
| CA2723207C (en) | Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease | |
| RU2328494C2 (ru) | Замещенные пиперазины, (1,4)-диазепины и 2,5-диазабицикло[2.2.1]гептаны в качестве н1-и/или н3-антагонистов гистамина или обратных н3-антагонистов гистамина | |
| RU2007140552A (ru) | НОВЫЕ ПРОИЗВОДНЫЕ 5, 7-ДИЗАМЕЩЕННОГО [1,3]ТИАЗОЛО[4,5-d]ПИРИМИДИН-2(3H)-ОНА | |
| RS52522B (en) | 1-ALKYL-1-AZONIABICYCLE DERIVATIVES / 2.2.2. / OCTAN CARBAMATE AND THEIR USE AS AN ANTAGONIST OF MUSCAR RECEPTORS | |
| BRPI0820112B8 (pt) | derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento | |
| HRP20120505T1 (hr) | Supstituirani n fenilmetil oksoprolin amidi kao antagonisti receptora p x i postupci njihove upotrebe | |
| RU2009120229A (ru) | Производные хинуклидинола в качестве антагонистов мускариновых рецепторов | |
| RU2011147200A (ru) | Азетидинилдиамиды в качестве ингибиторов моноациглицерин-липазы | |
| PE20121352A1 (es) | Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 | |
| CA2758474A1 (en) | Novel p2x7r antagonists and their use | |
| JP2008535834A5 (ru) | ||
| KR950701323A (ko) | 1-피페라지노-1,2-디히드로인덴 유도체(1-Piperazino-1,2-dihydroindene Derivatives) | |
| HRP20130918T1 (hr) | Derivati 4-aminopirimidina kao receptori antagonista histamina h4 | |
| RU2014126341A (ru) | СОЕДИНЕНИЯ ТИЕНИЛ[3, 2-d]ПИРИМИДИН-4-ОН, СПОСОБ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ | |
| RU2009103300A (ru) | Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии | |
| AU2010217615A1 (en) | Uses of NK receptor antagonists | |
| BRPI0517412A (pt) | derivados de benzodiazepina substituìdos | |
| WO2006026204A3 (en) | Novel gamma-lactams as beta-secretase inhibitors | |
| RU2009103321A (ru) | Применение 2-бензоилимидазопиридинов в терапии | |
| ES2322046T3 (es) | 6,7-dihidro-5h-pirazolo-(1,2a)pirazol-1-onas que controlan citoquinas inflamatorias. | |
| RU2009109100A (ru) | НОВЫЕ 5,7-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ [1,3]ТИАЗОЛО[4,5-d]ПИРИМИДИН-2(3Н)-ОНА И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| EA201992341A1 (ru) | Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов | |
| RU2008102155A (ru) | ЗАМЕЩЕННЫЕ 3-СУЛЬФОНИЛ-[1,2,3]ТРИАЗОЛО[1,5-a]ПИРИМИДИНЫ-АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТ6 РЕЦЕПТОРОВ, ЛЕКАРСТВЕННАЯ СУБСТАНЦИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |